Ahmedabad pharma: branded chronic-therapy drugs domestically, 6 plants making injectables and biologics.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 1.3k | 1.6k | 1.9k | 2.2k | 2.6k | 2.8k | 3.1k | 3.9k |
| Borrowings | 0 | 7 | 84 | 877 | 2.8k | 2.5k | 2.4k | 2.4k |
| Other Liabilities | 205 | 202 | 233 | 337 | 1.4k | 1.4k | 1.7k | 1.1k |
| Total Liabilities | 1.5k | 1.8k | 2.2k | 3.4k | 6.7k | 6.7k | 7.2k | 7.4k |
| AssetsFixed Assets | 875 | 854 | 918 | 2.6k | 4.3k | 5.3k | 5.2k | 5.2k |
| CWIP | 4 | 2 | 27 | 22 | 20 | 67 | 122 | 171 |
| Investments | 78 | 294 | 520 | 37 | 16 | 67 | 68 | 62 |
| Other Assets | 544 | 636 | 761 | 783 | 2.4k | 1.3k | 1.8k | 1.9k |
| Total Assets | 1.5k | 1.8k | 2.2k | 3.4k | 6.7k | 6.7k | 7.2k | 7.4k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 223 | 271 | 375 | 378 | 292 | 486 | 1.1k | 538 |
| Cash from Investing | -5 | 123 | -323 | -320 | -975 | -1.8k | -78 | -369 |
| Cash from Financing | -221 | -335 | -82 | -45 | 688 | 1.4k | -881 | -314 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 186 | 125 | 350 | 258 | -550 | 357 | 910 | 241 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (37.7×) and current (32.1×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 20.2% growth and a 32× exit, ₹1448 only delivers your return if you pay ₹1,633. The price is currently baking in 18% growth.
EPS grows 20.2%/yr for 5 years, then fades to 6% over 2, exits at 32×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 20.2% | 54.25 |
| FY28 | 20.2% | 65.20 |
| FY29 | 20.2% | 78.38 |
| FY30 | 20.2% | 94.21 |
| FY31 | 20.2% | 113.24 |
| FY32 | 13.1% ·fade | 128.07 |
| FY33 | 6.0% ·fade | 135.76 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.